Answer
Product information advises against breastfeeding during treatment and for a period afterwards because infant evidence remains limited. Discuss your circumstances with the specialist team.
Sources for this answer
- Ruxience 100 mg concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics
- MabThera 1400 mg Solution for Subcutaneous Injection — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.